Company intelligence / Profile preview

ResVita Bio

Berkeley, California, United Statesresvitabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ResVita Bio has received NIH grants to develop treatments for Netherton Syndrome and severe atopic dermatitis. The company has received Rare Pediatric Disease Designation for Netherton Syndrome from the FDA and is preparing to enter clinical trials in 2025.

Therapeutic areas: Dermatology
Modalities: Genetically engineered bacteriaTopical cell therapyProtein therapy
Industry: Biotech

Drug pipeline

3 assets

RVB-003

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ResVita Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ResVita Bio.

Explore the full profile